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BJU Editorial 
Optimal thromboprophylaxis remains a challenge 
 
The “Guidelines of guidelines: thromboprophylaxis for urologic surgery”, published in this month’s issue 
of BJUI by Violette et al. (1), addresses a critical issue in urologic practice and offers a comprehensive 
overview of available guidelines. Many urologic surgeries, especially cancer surgeries, present a 
significant risk of thromboembolism as well as bleeding. Therefore, urologic surgeons should be well 
educated in the matter in order to be able to offer optimal prophylaxis to patients. Reading through the 
current recommendations and guidelines, one realizes the wide variety of possible ways to risk stratify 
a patient, but also the large differences in opinions on how and when to offer prophylaxis. As a 
consequence, even members within the same national society might treat their patients in completely 
different ways. 
 
The ideal recommendation will have to be individualized, taking thromboembolic and bleeding risk into 
account for each individual patient and specific surgery type. This stratification of patients not only 
presents a challenge in clinical practice but also for the design of meaningful clinical trials. Since many 
medical questions regarding thromboprophylaxis remain unanswered, the currently available 
recommendations are based on our pathophysiologic understanding. In summary, they remain 
eminence-based rather than evidence-based. 
 
For many years, the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College 
of Chest Physicians Evidence-Based Clinical Practice Guidelines (2) were viewed as the most respected 
guidelines in surgery. They include recommendations for a wide variety of surgical procedures, including 
urologic surgeries. With an aging population, our patients will more often be on anticoagulant treatment 
before surgery. While most guidelines still recommend stopping the anticoagulant treatment and 
bridging with heparin, new evidence from randomized controlled trials (3,4) indicate that bridging by 
heparin significantly increases the risk for major bleeding without reducing the thromboembolic risk in 
most patients. Despite a recent appeal by internists and cardiologists (5) revised guidelines from the 
American College of Chest Physicians to replace the partially outdated recommendations have yet to 
be published. As mentioned by Violette et al. in their current review, bridging should probably only be 
offered to a limited number of patients with a very high risk for thromboembolic complications.  
 
Whether the recommendations for ASS prophylaxis will be changed similarly (to stopping perioperatively 
in all but high risk patients) is less clear (6). More clinical evidence is needed here. 
 
The EAU has recognized the problem and presented the prospect of providing a guideline on 
thromboprophylaxis for urologic procedures later this year. Looking at the landscape of available high 
quality publications it will still be highly challenging to provide clear recommendations for urologic 
surgeries. The key to a comprehensive application will be the clinical practicality. With this review, the 
authors have set the stage to a critical review of the recommendations from a urologic point of view.  
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